The Australia and New Zealand Cardio-Oncology Registry: evaluation of chemotherapy-related cardiotoxicity in a national cohort of paediatric cancer patients
Daniel Lapirow, Andre La Gerche, Claudia Toro, Emma Masango, Ben Costello, Enzo Porello, Louise Ludlow, Glenn Marshall, Toby Trahair, Marion Mateos, Jeremy Lewin, Jennifer Byrne, Rose Boutros, Rebecca Manudhane, John Heath, Julian Ayer, Melissa Gabriel, Thomas Walwyn, Jelena Saundankar, Jonathon Forsey Show all
INTERNAL MEDICINE JOURNAL | WILEY | Published : 2021
Cancer therapy related cardiac dysfunction (CTRCD) is an area of increasing focus, particularly during the survivorship period, for paediatric, adolescent and adult cancer survivors. With the advent of immunotherapy and targeted therapy, there is a new set of mechanisms from which paediatric and young adult patients with cancer may suffer cardiovascular injury. Furthermore, cardiovascular disease is the leading cause of morbidity and mortality in the survivorship period. The recently established Australian Cardio-Oncology Registry is the largest and only population-based cardiotoxicity database of paediatric and adolescent and young adult oncology patients in the world, and the first paediat..View full abstract
The ACOR steering committee and principal investigators acknowledge the patients and families that contributed to this research. Thanks to Professor Melissa Little, the Theme Director of Cell Biology and the Cardiac Regeneration laboratory at the Murdoch Children's Research Institute and the Clinician Scientist Fellowship Scheme at the Murdoch Children's Research Institute. The study data was collected and managed using REDCap electronic data capture tools hosted at Murdoch Children's Research Institute. The ACOR is funded through grants from The Royal Children's Hospital Foundation, The Royal Australasian College of Physicians and Kids Cancer Project. The authors have no industrial links or affiliations.